On June 2, Novo Nordisk fell 3.17% in regular trading, trading at $43.375/share, with trading volume of $302 million. The decline marks a second consecutive session of losses as the broader pharmaceutical sector remained under pressure.

On the news front, multiple headwinds continued to weigh on the stock. The pharmaceutical sector broadly declined, with Eli Lilly down 1.43%, Pfizer down 0.96%, and Zoetis down 1.52%. More critically, the competitive landscape in the obesity drug space has deteriorated further for Novo Nordisk. Eli Lilly's triple agonist retatrutide delivered Phase 3 data showing up to 28.3% weight loss, significantly surpassing Novo Nordisk's CagriSema at 22.7%. Additionally, Brazil has approved an Ozempic biosimilar priced 30% below the branded version, intensifying pricing pressure on Novo Nordisk's core revenue driver.

Market concerns over Novo Nordisk's pipeline competitiveness persist, as the obesity drug race increasingly tilts in favor of Eli Lilly.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)